Treatment strategy | Outcomes of Partitioned Survival Models | Incremental Changes | |||
---|---|---|---|---|---|
Intervention: Pemigatinib | Comparator 1: mFOLFOX | Comparator 2: 5-FU | Pemigatinib vs. mFOLFOX | Pemigatinib vs 5-FU | |
Cost | 4,177,572 | 749,130 | 524,472 | 3,428,442 | 3,653,100 |
 Total cost of PF state | 3,780,469 | 577,970 | 369,229 | 3,202,499 | 3,411,240 |
  Medication cost | 3,514,168 | 187,675 | 63,430 | 3,326,493 | 3,450,738 |
  Nonmedication cost | 276,301 | 390,294 | 305,799 | − 123,993 | − 39,498 |
 Total cost of PD state | 397,103 | 171,160 | 155,243 | 225,943 | 241,860 |
LY | |||||
 PF state | 0.81 | 0.46 | 0.36 | 0.35 | 0.45 |
 Overall | 1.61 | 0.80 | 0.67 | 0.81 | 0.94 |
QALY | |||||
 PF state | 0.61 | 0.33 | 0.26 | 0.28 | 0.35 |
 Overall | 1.15 | 0.56 | 0.47 | 0.59 | 0.68 |
ICER | |||||
 Incremental cost per LY gained |  |  |  | 4,238,063 | 3,888,175 |
 Incremental cost per QALY gained |  |  |  | 5,814,700 | 5,380,241 |
INMB | |||||
 LY |  |  |  | − 1,059,333 | − 901,589 |
 QALY |  |  |  | − 1,701,710 | − 1,664,647 |
EVPI/person | Â | Â | Â | 43,139 | 23,608 |